Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online May 1, 2007
Diabetes 56:2169-2173, 2007
DOI: 10.2337/db07-0052
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Appendix
Right arrow All Versions of this Article:
db07-0052v1
56/8/2169    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Callewaert, H. I.
Right arrow Articles by Mathieu, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Callewaert, H. I.
Right arrow Articles by Mathieu, C.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Brief Report

Deletion of STAT-1 Pancreatic Islets Protects Against Streptozotocin-Induced Diabetes and Early Graft Failure but Not Against Late Rejection

Hanne I. Callewaert1, Conny A. Gysemans1, Laurence Ladrière2, Wannes D'Hertog1, Julianna Hagenbrock1, Lutgart Overbergh1, Decio L. Eizirik2, and Chantal Mathieu1

1 Laboratory of Experimental Medicine and Endocrinology, Campus Gasthuisberg O&N, Catholic University of Leuven, Leuven, Belgium
2 Laboratory of Experimental Medicine, Université Libre de Bruxelles, Brussels, Belgium

Address correspondence and reprint requests to Dr. Chantal Mathieu, Laboratory of Experimental Medicine and Endocrinology, Campus Gasthuisberg O&N 1, Catholic University of Leuven, Herestraat 49, Bus 902, B-3000 Leuven, Belgium. E-mail: chantal.mathieu{at}uz.kuleuven.ac.be

Abbreviations: CsA, cyclosporine A; IL, interleukin; IL-1Ra, IL-1 receptor antagonist; IFN, interferon; iNOS, inducible nitric oxide synthase; IP-10, interferon-{gamma}–inducible protein-10; PNF, primary islet nonfunction; STAT, signal transducer and activator of transcription; STZ, streptozotocin

OBJECTIVE—Exposure of ß-cells to inflammatory cytokines leads to apoptotic cell death through the activation of gene networks under the control of specific transcription factors, such as interferon-{gamma}–induced signal transducer and activator of transcription (STAT)-1. We previously demonstrated that ß-cells lacking STAT-1 are resistant to cytokine-induced cell death in vitro. The aim of this study was to investigate the effect of STAT-1 elimination on immune-mediated ß-cell destruction in vivo.

RESEARCH DESIGN AND METHODS—Multiple low-dose streptozotocin (STZ) was given to C57BL/6 mice after syngeneic STAT-1–/– or wild-type islet transplantation. STAT-1–/– and wild-type islets were also transplanted in alloxan-diabetic BALB/c and spontaneously diabetic nonobese diabetic (NOD) mice. Additionally, mice were treated with interleukin (IL)-1 blockade (IL-1 receptor antagonist [IL-1ra]) and low-dose T-cell suppression (cyclosporine A [CsA]).

RESULTS—When exposed to multiple low-dose STZ in an immune-competent host, STAT-1–/– islets were more resistant to destruction than wild-type islets (28 vs. 100% diabetes incidence, P ≤ 0.05). STAT-1 deletion also protected allogeneic islet grafts against primary nonfunction in autoimmune NOD mice (0 vs. 17% using wild-type islets). However, no difference in survival time was observed. Additionally, treating recipients with IL-1ra and CsA prolonged graft survival in chemically diabetic BALB/c mice, whereas no difference was seen between STAT-1–/– and C57BL/6 grafts.

CONCLUSIONS—These data indicate that STAT-1 is a key player in immune-mediated early ß-cell dysfunction and death. When considering the many effector mechanisms contributing to ß-cell death following islet transplantation, multiple combined interventions will be needed for prolongation of ß-cell survival in the autoimmune context of type 1 diabetes.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.